News
Podcast
Author(s):
In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.
00:55 - Omnipod Updates at ATTD
14:00 - Updates on Benefits of Control IQ Algorithm
21:35 - Simplified Meal Approach Using Hybrid Closed-loop Insulin Delivery in Youth and Young Adults With Type 1 Diabetes (SMASH)
24:15 - Neural Network AID Algorithm
Automated Insulin Delivery, often referred to as AID, was a concept once akin to science fiction, but thanks to the dedication of specialists and researchers to advancing the field, has become a reality for people with diabetes.
Coming more than a decade and half after the approval of the first continuous glucose monitor in 1999, the FDA’s approval of the MiniMed 670G hybrid close loop system in 2016 signaled a major shift in realm of diabetes technology. Since this approval, 6 additional systems have received clearance from the FDA, with the most recent coming in the form of the twiist, which is marketed by Sequel Med Tech.
In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center provide insight from all things AID from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.
Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.
